| Q45228579 | A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines |
| Q36448142 | A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011 |
| Q40175603 | Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses |
| Q35618835 | Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases |
| Q36445557 | Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery |
| Q47547452 | Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. |
| Q30370445 | Adenoviral vectors as novel vaccines for influenza. |
| Q36935134 | Adenoviral vectors for gene therapy |
| Q47867006 | Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice |
| Q37378133 | Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses |
| Q40320327 | Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection |
| Q37661779 | Adenovirus serotype 5 vaccine vectors trigger IL-27-dependent inhibitory CD4+ T cell responses that impair CD8+ T cell function |
| Q40319132 | Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions |
| Q44051139 | Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. |
| Q27001601 | Adenovirus vectors for gene therapy, vaccination and cancer gene therapy |
| Q35599319 | Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors |
| Q37689799 | Adenovirus-vectored vaccines |
| Q40213253 | Adenoviruses use lactoferrin as a bridge for CAR-independent binding to and infection of epithelial cells |
| Q38808823 | Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer |
| Q38480709 | Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa |
| Q92006899 | Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo |
| Q36559904 | Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors |
| Q36504789 | An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models |
| Q44446461 | Anti-adenovirus humoral responses influence on the efficacy of vaccines based on epitope display on adenovirus capsid |
| Q58770917 | Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration |
| Q92058791 | Artificially cloaked viral nanovaccine for cancer immunotherapy |
| Q41842410 | Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile |
| Q27664198 | Atomic Structure of Human Adenovirus by Cryo-EM Reveals Interactions Among Protein Networks |
| Q40103248 | Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. |
| Q39342777 | Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses |
| Q34504791 | Biological challenges and technological opportunities for respiratory syncytial virus vaccine development |
| Q45353738 | Biomineralization-based virus shell-engineering: towards neutralization escape and tropism expansion |
| Q64376688 | Bovine adenovirus vectored vaccine for avian influenza |
| Q37698282 | CD8(+) T Cell Responses to Plasmodium and Intracellular Parasites |
| Q34657290 | Challenges in the development of an HIV-1 vaccine |
| Q28081164 | Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability |
| Q45876668 | Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies |
| Q64378726 | Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera |
| Q40226617 | Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon |
| Q34612406 | Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV. |
| Q45401922 | Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys |
| Q26995655 | Circumventing antivector immunity: potential use of nonhuman adenoviral vectors |
| Q42003390 | Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens |
| Q43713645 | Co-administration of viral vector-based vaccines suppresses antigen-specific effector CD8 T cells |
| Q34297930 | Cofactors that may influence vaccine responses |
| Q40932021 | Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development |
| Q58699767 | Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy |
| Q36559772 | Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors |
| Q35857420 | Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D |
| Q34289005 | Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China |
| Q45396135 | Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies |
| Q36756690 | Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques |
| Q35967313 | Conditionally replicating adenoviruses for cancer treatment. |
| Q30616830 | Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment |
| Q42237670 | Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon |
| Q39510185 | Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon |
| Q27335395 | CryoEM visualization of an adenovirus capsid-incorporated HIV antigen |
| Q36449189 | Current and novel approaches to vaccine development against tuberculosis |
| Q34502108 | Current progress in the development of a prophylactic vaccine for HIV-1. |
| Q39690078 | DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity |
| Q40256121 | Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses |
| Q28730757 | Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination |
| Q26782083 | Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs |
| Q27676519 | Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters |
| Q34120794 | Development of a targeted gene vector platform based on simian adenovirus serotype 24. |
| Q36966327 | Development of an Ad5H3 Chimera Using the "Antigen Capsid-Incorporation" Strategy for an Alternative Vaccination Approach |
| Q35638608 | Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. |
| Q36728793 | Development of vaccines for Marburg hemorrhagic fever |
| Q38582090 | Developments in Viral Vector-Based Vaccines |
| Q35113347 | Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines |
| Q36562614 | Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. |
| Q35363320 | Durable mucosal simian immunodeficiency virus-specific effector memory T lymphocyte responses elicited by recombinant adenovirus vectors in rhesus monkeys |
| Q39926337 | Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer |
| Q37191942 | Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo. |
| Q35857215 | Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors |
| Q34067641 | Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses |
| Q43591184 | Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. |
| Q45875654 | Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity |
| Q27664711 | Elicitation of structure-specific antibodies by epitope scaffolds |
| Q34146469 | Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency |
| Q37567831 | Engineered adenovirus serotypes for overcoming anti-vector immunity |
| Q35285887 | Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. |
| Q43280610 | Epitope mapping and cross-reactivity analysis of the monoclonal antibodies against hexon protein of human adenovirus type 3. |
| Q35446777 | Experimental models to study lymphatic and blood vascular metastasis |
| Q38400878 | Exploring evidence for behavioral risk compensation among participants in an HIV vaccine clinical trial |
| Q40197794 | Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence |
| Q34209026 | First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002) |
| Q39173602 | Fowl adenovirus: history, emergence, biology and development of a vaccine against hydropericardium syndrome |
| Q40082252 | Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies |
| Q64086675 | Genetic strategy to decrease complement activation with adenoviral therapies |
| Q64377562 | Genital CD8+ T cell response to HIV-1 gag in mice immunized by mucosal routes with a recombinant simian adenovirus |
| Q39437315 | Getting genetic access to natural adenovirus genomes to explore vector diversity |
| Q37851950 | HIV vaccines: progress to date. |
| Q35745815 | HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. |
| Q33642318 | HIV-1 vaccine development after STEP. |
| Q36718578 | HIV-1 vaccine development: progress and prospects |
| Q30356074 | HIV/AIDS epidemiology, pathogenesis, prevention, and treatment |
| Q37344236 | HIV/AIDS vaccines: a need for new concepts? |
| Q45325213 | Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps? |
| Q33740415 | Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting |
| Q54217812 | Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. |
| Q37461371 | Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects |
| Q34204440 | Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors |
| Q52650478 | Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. |
| Q34057708 | Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors |
| Q48105494 | Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum |
| Q36726723 | High road, low road? Choices and challenges on the pathway to a malaria vaccine |
| Q36058021 | Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon |
| Q35104823 | Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells |
| Q58759854 | Human adenovirus type 17 from species D transduces endothelial cells and human CD46 is involved in cell entry |
| Q36498186 | Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". |
| Q39229099 | Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy |
| Q37730925 | Humoral immunity in the Friend retrovirus infection model |
| Q47593481 | Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon |
| Q39940402 | Identification of a neutralization epitope in the VP1 capsid protein of SV40. |
| Q37123522 | Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors |
| Q37291653 | Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer |
| Q91782856 | Identification of novel human adenovirus candidates using the coxsackievirus and adenovirus receptor for cell entry |
| Q37189696 | Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells. |
| Q40333540 | Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity |
| Q34235198 | Impact of MHC class I diversity on immune control of immunodeficiency virus replication |
| Q37333347 | Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice |
| Q35085363 | Implications of the innate immune response to adenovirus and adenoviral vectors |
| Q57175561 | Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs |
| Q37945219 | Improving adenovirus based gene transfer: strategies to accomplish immune evasion |
| Q35641791 | Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies |
| Q27485003 | Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine |
| Q35317858 | Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine |
| Q45369052 | Infant lungs are preferentially infected by adenovirus and herpes simplex virus type 1 vectors: role of the tissue mesenchymal cells |
| Q47242905 | Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding |
| Q37287424 | Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization |
| Q36645405 | Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors |
| Q56447686 | International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials |
| Q35112755 | International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations |
| Q37545021 | Intramuscular delivery of adenovirus serotype 5 vector expressing humanized protective antigen induces rapid protection against anthrax that may bypass intranasally originated preexisting adenovirus immunity |
| Q40925240 | Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice. |
| Q33630150 | Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses |
| Q36001347 | Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission |
| Q43183487 | Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys |
| Q35097577 | Mammalian production of an isotopically enriched outer domain of the HIV-1 gp120 glycoprotein for NMR spectroscopy. |
| Q35557004 | Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo |
| Q37984486 | Manipulation of adenovirus interactions with host factors for gene therapy applications |
| Q37310677 | Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model |
| Q36142504 | Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity |
| Q27666306 | Model of the Trimeric Fiber and Its Interactions with the Pentameric Penton Base of Human Adenovirus by Cryo-electron Microscopy |
| Q34229968 | Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses |
| Q34697474 | Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide |
| Q35066303 | Modulation of plasmid DNA vaccine antigen clearance by caspase 12 RNA interference potentiates vaccination |
| Q44875671 | Molecular characterization of adenoviruses in fecal samples of captively bred rhesus macaques in China |
| Q33353795 | Molecular engineering of viral gene delivery vehicles |
| Q92034605 | Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy |
| Q33712578 | Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys |
| Q64374798 | Mucosal adenovirus-vectored vaccine for measles |
| Q34457800 | Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors |
| Q92290331 | Nanoparticle Vaccines for Inducing HIV-1 Neutralizing Antibodies |
| Q37426321 | Nanoparticle-detained toxins for safe and effective vaccination |
| Q21092172 | Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice |
| Q37619767 | Native and engineered tropism of vectors derived from a rare species D adenovirus serotype 43. |
| Q58734504 | New Adenovirus Groups in Western Palaearctic Bats |
| Q37513550 | New insights on adenovirus as vaccine vectors |
| Q24567699 | New viruses for cancer therapy: meeting clinical needs |
| Q35099708 | Next generation: tuberculosis vaccines that elicit protective CD8+ T cells |
| Q47112156 | Novel Concepts for HIV Vaccine Vector Design |
| Q34257640 | Novel adenovirus vector-based vaccines for HIV-1 |
| Q30378897 | Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. |
| Q26776553 | Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications |
| Q55365677 | One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors. |
| Q42064105 | Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. |
| Q34746476 | Oral adenoviral-based vaccines: historical perspective and future opportunity |
| Q37603360 | Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors |
| Q24635276 | PEGylated Adenoviruses: From Mice to Monkeys |
| Q45888470 | Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys |
| Q44137633 | Pre- and post-exposure protection against Western equine encephalitis virus after single inoculation with adenovirus vector expressing interferon alpha |
| Q38284700 | Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?. |
| Q38061876 | Pre-existing immunity against vaccine vectors--friend or foe? |
| Q27304910 | Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses |
| Q36154059 | Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials |
| Q36141586 | Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine |
| Q37167960 | Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors |
| Q34552488 | Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV. |
| Q36662462 | Progress and obstacles in the development of an AIDS vaccine |
| Q64376803 | Progress in Adenoviral Capsid-Display Vaccines |
| Q34358402 | Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon |
| Q33684288 | Protection of non-human primates against rabies with an adenovirus recombinant vaccine |
| Q37333924 | Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys |
| Q36315185 | Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. |
| Q40084604 | Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations. |
| Q34162092 | Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice |
| Q36464587 | Replicating and non-replicating viral vectors for vaccine development |
| Q40188439 | Rescue of chimeric adenoviral vectors to expand the serotype repertoire |
| Q56893551 | Respiratory syncytial virus vaccine development |
| Q40757700 | Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. |
| Q99240705 | SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies |
| Q37130450 | STEP trial and HIV-1 vaccines inducing T-cell responses |
| Q50079113 | Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system |
| Q52572435 | Scavenger receptor-mediated Ad5 entry and acLDL accumulation in monocytes/macrophages synergistically trigger innate responses against viral infection. |
| Q36872938 | Scientific and policy challenges to development of an AIDS vaccine |
| Q40170219 | Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China |
| Q39581144 | Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. |
| Q36171914 | Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions |
| Q27318575 | Single-Dose Mucosal Immunization with a Candidate Universal Influenza Vaccine Provides Rapid Protection from Virulent H5N1, H3N2 and H1N1 Viruses |
| Q45401900 | Single-dose, fast-acting vaccine candidate against western equine encephalitis virus completely protects mice from intranasal challenge with different strains of the virus |
| Q38618197 | Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies |
| Q36714652 | Status and challenges of filovirus vaccines |
| Q37503253 | Strategies to overcome host immunity to adenovirus vectors in vaccine development |
| Q42259707 | Structure-based identification of a major neutralizing site in an adenovirus hexon |
| Q39971490 | Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver |
| Q45869559 | Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients |
| Q37924616 | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| Q34487264 | Synthetic virology: engineering viruses for gene delivery |
| Q35226101 | Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model |
| Q37693810 | T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load |
| Q36837129 | T-cell immunity generated by recombinant adenovirus vaccines |
| Q42131157 | TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector |
| Q92622099 | Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice |
| Q37227135 | Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody |
| Q38959835 | The Density Code for the Development of a Vaccine? |
| Q58750585 | The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road |
| Q34289823 | The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert |
| Q24652185 | The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? |
| Q38230901 | The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery |
| Q34077543 | The influence of delivery vectors on HIV vaccine efficacy |
| Q33655401 | The influence of innate and pre-existing immunity on adenovirus therapy |
| Q36023055 | The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes |
| Q43244982 | Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination |
| Q36736465 | Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis |
| Q38614156 | Tropism-modification strategies for targeted gene delivery using adenoviral vectors |
| Q36780156 | Use of viral vectors for the development of vaccines |
| Q28744027 | Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality |
| Q36246264 | Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys |
| Q41097174 | Vaccine Engineering with Dual-Functional Mineral Shell: A Promising Strategy to Overcome Preexisting Immunity |
| Q51204803 | Vaccines: engineering immune evasion. |
| Q37158473 | Vaccinia virus, a promising new therapeutic agent for pancreatic cancer |
| Q91408185 | Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes |
| Q34134445 | Virology. Looking inside adenovirus |
| Q37646066 | Viruses as vaccine vectors for infectious diseases and cancer |
| Q30478392 | Visualization of alpha-helices in a 6-angstrom resolution cryoelectron microscopy structure of adenovirus allows refinement of capsid protein assignments |
| Q35147685 | Vitamin A deficiency impairs vaccine-elicited gastrointestinal immunity |
| Q45875332 | Wild-type adenoviruses from groups A-F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent |